Search
Group A Streptococcus (GAS) M protein is an important virulence factor and potential vaccine antigen, and constitutes the basis for strain typing (emm-typing).
Vaccine prevention of GAS infections and their immunological complications has been a goal of researchers for decades.
No currently licensed and available vaccine has been shown to provide broad protection against endemic MnB disease.
The desire for an effective vaccine arises from the large burden of disease caused by the bacterium, particularly rheumatic fever and rheumatic heart disease.
A bivalent, recombinant, factor H-binding protein (rLP2086) vaccine was developed to protect against invasive Neisseria meningitidis serogroup B (MnB) in...
Neisseria meningitidis is a leading cause of meningitis and septicaemia, but a broadly-protective vaccine against endemic serogroup B disease is not licensed...
Viral respiratory infections are associated with significant morbidity and mortality.
Head, Vaccine Trials Group
An international team of researchers has pioneered a technique which gives unprecedented insight into the dramatic changes occurring in a baby’s body in the first week of life.
The major funder of the Wesfarmers Centre of Vaccines and Infectious Diseases based at The Kids Research Institute Australia has been recognised as Australia’s most generous giver.